BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma
详细信息 查看全文
- 作者：Justus Lieber ; Verena Ellerkamp ; Fabian Vogt ; Julia Wenz ; Steven W. Warmann ; J枚rg Fuchs ; Sorin Armeanu-Ebinger
- 关键词：HB ; hepatoblastoma ; SR ; standard risk ; HR ; high risk ; MDR ; multi drug resistance ; CDDP ; cisplatin ; BH3 ; Bcl-2 homology domain
- 刊名：Experimental Cell Research
- 出版年：10 March, 2014
- 年：2014
- 卷：322
- 期：1
- 页码：217-225
- 全文大小：9081 K
文摘
Drug resistance and metastasis remain major challenges in the treatment of high-risk hepatoblastoma (HB) and require the development of alternative therapeutic strategies. Modulation of apoptosis in HB cells enhances the sensitivity of these cells towards various drugs and has been discussed to enforce treatment. We investigated the impact of apoptosis sensitisers, BH3-mimetics, on the interaction between the host and HB to reduce tumour growth and dissemination while enhancing immunity. BH3-mimetics, such as obatoclax and ABT-737, enhanced the apoptosis-inducing effect of TRAIL and TNF-伪 resistant HB cells (HepT1 and HUH6). Tumour cell migration was inhibited by ABT-737 and more markedly by obatoclax. In an orthotopic model of HB, tumour uptake was reduced when the cells were pretreated with low concentrations of obatoclax. Only 1 of 7 mice developed HB in the liver, compared with an incidence of 0.8 in the control group. In summary, our study showed that apoptosis sensitisers had broader effects on HB cells than expected including migration and susceptibility to cytokines in addition to the known effects on drug sensitization. Sensitising HB to apoptosis may also allow resistant HB to be targeted by immune cells and prevent tumour cell dissemination.